Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC)

NCT01818986 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Castrate-resistant Prostate Cancer
mCRPC

Interventions

DRUG: Sipuleucel-T
RADIATION: Stereotactic Ablative Body Radiation

Sponsor

University of Texas Southwestern Medical Center